Kura Oncology, Inc.

Precision-oncology company commercializing ziftomenib in NPM1-mutated AML and expanding it into frontline combination regimens.

Back to company catalog

Hematologic malignancies / precision oncology · Targeted small molecules · Commercial + Phase 3

Compare report options